Biodexa Pharmaceuticals (BDRX) Total Current Liabilities (2013 - 2025)

Biodexa Pharmaceuticals (BDRX) has 13 years of Total Current Liabilities data on file, last reported at $8.2 million in Q4 2025.

• For the quarter ending Q4 2025, Total Current Liabilities rose 26.18% year-over-year to $8.2 million; the trailing twelve-month figure through Dec 2025 stood at $8.2 million (up 26.18% YoY), and the FY2025 full-year result was $8.1 million, up 25.07% from the prior year.
• Total Current Liabilities climbed to $8.2 million in Q4 2025, from $3.3 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $8.2 million in Q4 2025 to a low of $2.1 million in Q2 2022.
• A 5-year average of $4.4 million and a median of $3.9 million in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities sank 61.41% in 2022 and soared 210.15% in 2023, its largest moves.
• Tracing BDRX's Total Current Liabilities over 5 years: stood at $2.5 million in 2021, then retreated by 10.2% to $2.2 million in 2022, then soared by 210.15% to $6.9 million in 2023, then dropped by 6.52% to $6.5 million in 2024, then advanced by 26.18% to $8.2 million in 2025.
• Business Quant data shows BDRX's Total Current Liabilities at $8.2 million in Q4 2025, $3.3 million in Q2 2025, and $6.5 million in Q4 2024.